Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings
Alternative Names: AmnioStem; AmnioStem universal donor stem cell; Amniotic fluid derived stem cell; Amniotic fluid stem cellsLatest Information Update: 28 Aug 2022
At a glance
- Originator Creative Medical Technology Holdings
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cachexia; Glioma; Primary ovarian insufficiency; Radiation injuries; Stroke
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Cachexia in USA (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Radiation-injuries in USA (Parenteral)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Glioma in USA (Parenteral)